Article

Matrix Metalloproteinase-9 Degrades Amyloid-β Fibrils in Vitro and Compact Plaques in Situ

Hope Center for Neurological Disorders, Washington University in St. Louis, San Luis, Missouri, United States
Journal of Biological Chemistry (Impact Factor: 4.57). 09/2006; 281(34):24566-74. DOI: 10.1074/jbc.M602440200
Source: PubMed

ABSTRACT The pathological hallmark of Alzheimer disease is the senile plaque principally composed of tightly aggregated amyloid-beta fibrils (fAbeta), which are thought to be resistant to degradation and clearance. In this study, we explored whether proteases capable of degrading soluble Abeta (sAbeta) could degrade fAbeta as well. We demonstrate that matrix metalloproteinase-9 (MMP-9) can degrade fAbeta and that this ability is not shared by other sAbeta-degrading enzymes examined, including endothelin-converting enzyme, insulin-degrading enzyme, and neprilysin. fAbeta was decreased in samples incubated with MMP-9 compared with other proteases, assessed using thioflavin-T. Furthermore, fAbeta breakdown with MMP-9 but not with other proteases was demonstrated by transmission electron microscopy. Proteolytic digests of purified fAbeta were analyzed with matrix-assisted laser desorption ionization time-of-flight mass spectrometry to identify sites of Abeta that are cleaved during its degradation. Only MMP-9 digests contained fragments (Abeta(1-20) and Abeta(1-30)) from fAbeta(1-42) substrate; the corresponding cleavage sites are thought to be important for beta-pleated sheet formation. To determine whether MMP-9 can degrade plaques formed in vivo, fresh brain slices from aged APP/PS1 mice were incubated with proteases. MMP-9 digestion resulted in a decrease in thioflavin-S (ThS) staining. Consistent with a role for endogenous MMP-9 in this process in vivo, MMP-9 immunoreactivity was detected in astrocytes surrounding amyloid plaques in the brains of aged APP/PS1 and APPsw mice, and increased MMP activity was selectively observed in compact ThS-positive plaques. These findings suggest that MMP-9 can degrade fAbeta and may contribute to ongoing clearance of plaques from amyloid-laden brains.

Download full-text

Full-text

Available from: Qingli Xiao, May 27, 2015
0 Followers
 · 
156 Views
  • Source
    • "Aβ-activated microglia release a wide variety of neurotoxic molecules including proinflammatory cytokines (Griffin, 2006), reactive oxygen species (Reddy et al., 2009), and complement proteins (Bonifati and Kishore, 2007), which contribute to the neurodegeneration in AD. On the other hand, microglia have beneficial effects against AD as a result of neurotrophic agent secretion and clearing Aβ by phagocytosis (Mizuno et al., 2004; Yan et al., 2006). In addition, in vitro experiments strongly suggest a role for microglia in phagocytic clearance of Aβ. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The purpose of this study was to evaluate the therapeutic potential of human induced pluripotent stem (iPS) cell-derived macrophage-like cells for Alzheimer’s disease (AD). In previous studies, we established the technology to generate macrophage-like myeloid lineage cells with proliferating capacity from human iPS cells, and we designated the cells iPS-ML. iPS-ML reduced the level of Aβ added into the culture medium, and the culture supernatant of iPS-ML alleviated the neurotoxicity of Aβ. We generated iPS-ML expressing the Fc-receptor-fused form of a single chain antibody specific to Aβ. In addition, we made iPS-ML expressing Neprilysin-2 (NEP2), which is a protease with Aβ-degrading activity. In vitro, expression of NEP2 but not anti-Aβ scFv enhanced the effect to reduce the level of soluble Aβ oligomer in the culture medium and to alleviate the neurotoxicity of Aβ. To analyze the effect of iPS-ML expressing NEP2 (iPS-ML/NEP2) in vivo, we intracerebrally administered the iPS-ML/NEP2 to 5XFAD mice, which is a mouse model of AD. We observed significant reduction in the level of Aβ in the brain interstitial fluid following administration of iPS-ML/NEP2. These results suggested that iPS-ML/NEP2 may be a potential therapeutic agent in the treatment of AD.
    Stem Cell Research 10/2014; 13(3). DOI:10.1016/j.scr.2014.10.001 · 3.91 Impact Factor
  • Source
    • "Human hippocampus, astrocytes, neurons (e.g., pyramidal neurons) [15] Neurons [24] Vascular walls of brains [28] Injured neurons, astrocytes, pericytes, reactive microglia/macrophages, and oligodendrocytes [25] Dendritic cells, glial cells [29] Hypothesized functions suggested in neurodegeneration processes MMP-3 might be involved in degeneration of neurons and formation of neurofibrillary tangles [13] Activated forms of MMP-9 may degrade extracellular substrates such as amyloid-␤ [23] Elevated brain concentrations of MMP-3 might result in the increased MMP-9 activity, and indirectly facilitate tau aggregation [26] [27] MMP-9 might be involved in degeneration of neurons and formation of neurofibrillary tangles [13] MMP-3 decreases oligomer aggregation by degrading tau in the regions that are crucial to the formation of fibrils [27] MMP-9 are possibly induced after plaque formation, and play a role in limiting plaque growth, causing plaques to reach an equilibrium at a given size [23] at the earlier stages of the neurodegeneration process, and stabilizes partially during the disease progress, yet remaining significantly altered in the AD stage compared to non-demented subjects. In any case, this result will have to be confirmed on larger, independent cohorts. "
    [Show abstract] [Hide abstract]
    ABSTRACT: A growing body of evidence shows the involvement of matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) in neurodegeneration processes, but reports of their concentrations in the cerebrospinal fluid (CSF) are inconsistent. Therefore, the aim of our study was to evaluate the CSF concentrations of MMP-2, MMP-3, MMP-9, and their inhibitors (TIMP-1 and TIMP-2) in carefully selected groups of patients with Alzheimer's disease (AD), mild cognitive impairment (MCI), and non-demented controls, whose clinical and neuropsychological diagnoses were confirmed by the corresponding CSF biomarkers of neurochemical dementia diagnostics: decreased concentrations of Aβ1-42 and/or Aβ42/40 ratio, and increased concentrations of Tau and pTau181 proteins. The study included 33 AD patients, 15 subjects with MCI, and 18 elderly individuals without cognitive deficits. The CSF concentrations of MMPs and TIMPs were determined with ELISAs. CSF concentrations of MMP-9 were significantly lower, and the concentrations of MMP-3 significantly higher in AD patients compared to the controls. Neither MMP-2 nor TIMPs showed significant changes among the groups investigated. Altered concentrations of two out of three MMPs investigated in this study suggest that this family of biomolecules may play a role in the AD pathophysiology. Further studies are needed to establish their potential diagnostic utility.
    Journal of Alzheimer's disease: JAD 01/2014; 40(2). DOI:10.3233/JAD-131634 · 4.15 Impact Factor
  • Source
    • "Fluctuation of the levels of AbPP proteolytic products could be associated with modulated expression and/or activity of enzymes implicated in AbPP processing. It was therefore, important to investigate whether the observed, oleuropein-mediated increase of sAPPa was a result of the effect of oleuropein on relative expression levels of the enzymes related with AbPP processing TACE, ADAM-10, BACE-1, MMP-2 or MMP-9 for which recent data indicate that it may act like a-secretase enzyme, contributing to the clearance of Ab (Yan et al. 2006; Talamagas et al. 2007; Fragkouli et al. 2011a; Fragkouli et al. 2011b). From the data obtained, no significant difference was observed in the levels of expression of TACE, ADAM-10, BACE-1, and MMP-2. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Over the past decade, intense focus has been dedicated on investigating processes involved in the proteolysis of amyloid precursor protein (AβPP) and β-amyloid (Aβ) peptide metabolism, as possible targets for Alzheimer's disease (AD) therapy. To this goal, considerable research has been targeted on potential therapeutic use of compounds promoting non-amyloidogenic processing of AβPP. One of these compounds, oleuropein, a polyphenol constituent of extra virgin olive oil exhibiting a wide range of pharmacological properties, was shown to interact non-covalently with Aβ, an interaction that might be related to a potential protective role of oleuropein against Aβ aggregation. In the present study, it was demonstrated that oleuropein treatment of HEK293 cells stably transfected with the isoform 695 of human AβPP (APP695) leads to markedly elevated levels of sAPPα and to significant reduction of Aβ oligomers. These effects were associated with increased activity of matrix metalloproteinase 9 (MMP-9), whereas no significant alterations in the expression of secretases TACE, ADAM-10 or BACE-1 were observed. Similar results were obtained using the human neuroblastoma cell line SK-N-SH. The experimental data reveal an anti-amyloidogenic effect of oleuropein and suggest a possible protective role for oleuropein against AD, extending the spectrum of beneficial properties of this naturally occurring polyphenol.
    Cellular and Molecular Neurobiology 10/2012; 33(1). DOI:10.1007/s10571-012-9880-9 · 2.20 Impact Factor
Show more